“Ninety percent of big pharma’s revenues are going to fall of the face of the planet in three years,” said Dr. Bijian Salehizadeh, a partner with venture capital firm Highland Capital Partners, which invests in early-stage biotech companies. “They have to turn somewhere --and it just happens to be in the direction of these small firms where all the ideas are being generated.”
More
No comments:
Post a Comment